Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
The objective of the Clinical Experience Investigation (CEI) is to collect following data to characterise safety and efficacy of LYMPARZA Tablets 100mg and 150mg (LYMPARZA) in usual post-marketing use.
1. Development of adverse drug reactions (ADRs)
2. Factors which may affect safety and efficacy of LYMPARZA
3. Development of adverse drug reactions (ADRs) unexpected from "Precautions for Use" of the LYMPARZA JPI
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Maintenance treatment for patients with recurrent ovarian cancer, who are sensitive to platinum based chemotherapy
You may not be if
\-
Clareo Health | Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)
